Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia
- PMID: 31385399
- DOI: 10.1111/resp.13663
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia
Abstract
Background and objective: Enterobacteriaceae (EB) spp. family is known to include potentially multidrug-resistant (MDR) microorganisms, and remains as an important cause of community-acquired pneumonia (CAP) associated with high mortality. The aim of this study was to determine the prevalence and specific risk factors associated with EB and MDR-EB in a cohort of hospitalized adults with CAP.
Methods: We performed a multinational, point-prevalence study of adult patients hospitalized with CAP. MDR-EB was defined when ≥3 antimicrobial classes were identified as non-susceptible. Risk factors assessment was also performed for patients with EB and MDR-EB infection.
Results: Of the 3193 patients enrolled with CAP, 197 (6%) had a positive culture with EB. Fifty-one percent (n = 100) of EB were resistant to at least one antibiotic and 19% (n = 38) had MDR-EB. The most commonly EB identified were Klebsiella pneumoniae (n = 111, 56%) and Escherichia coli (n = 56, 28%). The risk factors that were independently associated with EB CAP were male gender, severe CAP, underweight (body mass index (BMI) < 18.5) and prior extended-spectrum beta-lactamase (ESBL) infection. Additionally, prior ESBL infection, being underweight, cardiovascular diseases and hospitalization in the last 12 months were independently associated with MDR-EB CAP.
Conclusion: This study of adults hospitalized with CAP found a prevalence of EB of 6% and MDR-EB of 1.2%, respectively. The presence of specific risk factors, such as prior ESBL infection and being underweight, should raise the clinical suspicion for EB and MDR-EB in patients hospitalized with CAP.
Keywords: Enterobacteriaceae; community-acquired pneumonia; multidrug-resistance; prevalence; risk factors.
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Comment in
-
Community-acquired pneumonia due to drug-resistant Enterobacteriaceae: A global perspective.Respirology. 2020 May;25(5):468-469. doi: 10.1111/resp.13720. Epub 2019 Oct 23. Respirology. 2020. PMID: 31645083 No abstract available.
References
REFERENCES
-
- Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am. J. Respir. Crit. Care Med. 2015; 192: 597-604.
-
- World Healht Organization. The top 10 causes of death. [Accessed 4 Dec 2018.] Available from URL: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
-
- Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N. Engl. J. Med. 2014; 370: 543-51.
-
- Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007;44(Suppl. 2): S27-72.
-
- Faverio P, Aliberti S, Bellelli G, Suigo G, Lonni S, Pesci A, Restrepo MI. The management of community-acquired pneumonia in the elderly. Eur. J. Intern. Med. 2014; 25: 312-9.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous